LAKE FOREST, Ill., Dec. 20, 2018 (GLOBE NEWSWIRE) — Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that it has submitted to the U.S. Food and Drug Administration a 505(b)(2) New Drug Application for its novel injectable formulation of…Original Article
Assertio Therapeutics Announces Submission of NDA for FDA Approval of Cosyntropin Depot
